Report Highlights

South America's Role in the Global dry AMD Supply Chain

South America functions primarily as an end-market consumer in the global dry age-related macular degeneration supply chain, importing approximately 85% of advanced therapeutics from North American and European manufacturers. Brazil dominates regional import volumes, accounting for $312 million in dry AMD product imports in 2024, followed by Argentina ($89 million) and Colombia ($67 million). The region's pharmaceutical infrastructure centers around São Paulo and Buenos Aires distribution hubs, which serve as entry points for biologics requiring cold-chain logistics. Major multinational pharmaceutical companies maintain regional subsidiaries that handle regulatory compliance, local distribution partnerships, and physician education programs across the continent's fragmented healthcare systems.

The region's supply chain vulnerability became evident during the COVID-19 pandemic when import delays affected anti-VEGF therapy availability, highlighting dependency on external manufacturing. Local production capacity remains limited to basic formulations and packaging operations, with companies like Eurofarma in Brazil and Laboratorios Bagó in Argentina focusing on generic eye care products rather than advanced dry AMD therapeutics. Chile and Colombia have emerged as regional clinical trial hubs, conducting Phase II and III studies for global pharmaceutical companies, contributing valuable patient data while building local expertise. This clinical research activity positions these countries as early adopters of new therapies, creating pathways for accelerated regulatory approval and market access across the region.

Growth Drivers for South American dry AMD Trade and Production

Demographic transition represents the primary growth driver, with South America experiencing rapid population aging that directly correlates with increased dry AMD incidence. Brazil's population aged 65+ is projected to reach 22.7 million by 2030, creating substantial demand for advanced retinal therapies previously unavailable in regional markets. Healthcare infrastructure investments, particularly in Brazil's SUS system and Colombia's universal healthcare expansion, are enabling broader patient access to expensive dry AMD treatments through government procurement programs. Regional pharmaceutical companies are increasingly establishing manufacturing partnerships with global innovators, exemplified by Cristália Pharmaceuticals' collaboration with international partners to produce biosimilar anti-VEGF therapies, reducing import dependency and improving cost-effectiveness for healthcare systems across the region.

Regulatory harmonization initiatives through MERCOSUR and Pacific Alliance frameworks are streamlining drug approval processes, reducing time-to-market for new dry AMD therapies from 24 months to 12-15 months average approval timelines. Private healthcare sector growth, particularly in Chile and Uruguay, is driving demand for premium dry AMD treatments as affluent patient populations seek access to latest-generation complement inhibitors and emerging gene therapies. Technology transfer agreements are enabling local production of diagnostic equipment and imaging systems essential for dry AMD management, with companies like Brazilian manufacturer Opto establishing partnerships with global medical device companies to produce optical coherence tomography systems locally, reducing equipment costs and improving diagnostic accessibility across the region.

Supply Chain Risks and Trade Barriers

Currency volatility poses significant supply chain challenges, with the Brazilian real, Argentine peso, and Colombian peso experiencing substantial fluctuations that directly impact pharmaceutical import costs and pricing strategies. Import dependency creates vulnerability to global supply disruptions, as demonstrated during recent anti-VEGF shortages that forced healthcare systems to implement rationing protocols across multiple countries. Regulatory complexity varies significantly between countries, with differing approval requirements creating market access delays and increasing compliance costs for international pharmaceutical companies. Cold-chain infrastructure limitations in remote regions of Brazil, Peru, and Ecuador compromise biologics distribution, requiring expensive specialized logistics solutions that increase overall product costs and limit patient access in underserved areas.

Intellectual property enforcement inconsistencies across the region create risks for innovative pharmaceutical companies, particularly affecting investment decisions for local manufacturing facilities and technology transfer agreements. Import tariffs on pharmaceutical products range from 0% to 14% depending on country and product classification, creating pricing disparities that drive cross-border patient travel and parallel import activities. Healthcare budget constraints and reimbursement delays in public systems create cash flow challenges for distributors and limit market penetration of high-value dry AMD therapies. Political instability and changing healthcare policies, particularly evident in recent years across several South American countries, create regulatory uncertainty that affects long-term supply chain planning and investment commitments from multinational pharmaceutical companies.

Trade and Investment Opportunities in South America

Regional manufacturing partnerships present significant opportunities for pharmaceutical companies seeking to establish local production capabilities while reducing import costs and improving market access. Brazil's growing biotechnology sector, anchored by companies like Bionovis and Cristália, offers collaboration opportunities for biosimilar development and contract manufacturing services. Chile's stable regulatory environment and skilled workforce make it an attractive location for regional headquarters and distribution centers serving Pacific Alliance countries. Investment opportunities exist in specialized logistics infrastructure, particularly temperature-controlled warehousing and distribution networks capable of handling biologics across diverse geographic and climatic conditions throughout the continent.

Public-private partnerships for healthcare infrastructure development offer pathways for medical device companies to establish local assembly and service operations while supporting government healthcare modernization initiatives. Argentina's pharmaceutical manufacturing base provides opportunities for technology transfer agreements and joint ventures focused on producing generic formulations and diagnostic consumables for regional markets. Clinical research organizations are expanding rapidly across the region, creating opportunities for contract research services and specialized clinical trial management companies. Digital health platforms and telemedicine solutions represent emerging investment opportunities, particularly for companies developing remote monitoring systems and AI-powered diagnostic tools that can extend dry AMD care to underserved rural populations across South America's vast geographic territories.

Market at a Glance

Leading Market Participants

Regulatory and Trade Policy Environment

South America's regulatory landscape for dry AMD therapeutics operates through a complex framework of national agencies with varying approval requirements and timelines. Brazil's ANVISA leads regional standards with comprehensive biotechnology regulations that often serve as benchmarks for other countries, while Argentina's ANMAT and Colombia's INVIMA maintain distinct approval pathways that can create market access delays. MERCOSUR pharmaceutical harmonization initiatives have established mutual recognition agreements for certain therapeutic categories, reducing duplicate clinical trial requirements and enabling faster regional rollouts for approved dry AMD treatments. Import duty structures vary significantly, with most countries applying reduced tariffs to essential medicines while maintaining higher rates on medical devices and diagnostic equipment.

Intellectual property protection frameworks align with TRIPS agreement standards across most South American countries, though enforcement mechanisms and patent term extensions vary considerably. Chile's patent linkage system and data exclusivity protections provide robust innovation incentives, while Brazil's local working requirements and compulsory licensing provisions create different competitive dynamics. Price regulation mechanisms, including reference pricing systems in Colombia and Brazil's Economic Evaluation Chamber, significantly influence market access strategies for high-value dry AMD therapies. Recent healthcare policy reforms across the region emphasize universal coverage expansion and cost-effectiveness evaluation, creating new requirements for pharmacoeconomic evidence and outcomes-based pricing agreements that affect treatment accessibility and commercial viability.

South American dry AMD Supply Chain Outlook to 2032

Regional supply chain evolution will be characterized by increased local pharmaceutical manufacturing capabilities and reduced import dependency, driven by government policies promoting biotechnology sector development and technology transfer agreements. Brazil's National Biotechnology Policy and Colombia's pharmaceutical industry development initiatives are expected to attract significant foreign investment in local production facilities, particularly for biosimilar anti-VEGF therapies and complement inhibitors. Digital health infrastructure expansion will transform patient monitoring and treatment adherence, with telemedicine platforms and AI-powered diagnostic tools becoming integral components of dry AMD care delivery across remote and underserved areas.

Trade flow patterns will shift toward increased intra-regional commerce as local manufacturing capacity expands and regulatory harmonization progresses through expanded MERCOSUR and Pacific Alliance cooperation frameworks. Cold-chain logistics infrastructure investments will improve biologics distribution capabilities, while regional clinical trial networks will continue expanding, positioning South America as a key global hub for late-stage dry AMD therapy development. Currency hedging strategies and local procurement initiatives will reduce foreign exchange exposure, while public-private partnerships will drive healthcare infrastructure modernization. By 2032, the region is expected to achieve 40% local production capability for dry AMD therapeutics, compared to current levels below 15%, fundamentally altering competitive dynamics and improving patient access across all socioeconomic segments.